November 6, 2024 10:34 AM EST
News Briefing

Macro­Gen­ics paus­es de­vel­op­ment of ADC; Cel­lec­tis de­pri­or­i­tizes CAR-T

ENDPOINTS

Plus, news about Tan­go Ther­a­peu­tics, En­do, Neu­ro­gene and Cen­tu­ry Ther­a­peu­tics:

Macro­Gen­ics stopped dos­ing pa­tients in ADC tri­al: Af­ter three pa­tient deaths in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times